This report from AVAC is a clear and concise account of the results and implications of the world's first phase III efficacy trial of an HIV vaccine, the results of which were announced in February 2003. It is relevant for anyone engaged in the effort to test vaccine candidates in clinical trials - scientists, health care workers, community groups and policymakers alike.

Produced with the support of influential organisations including the Bill and Melinda Gates Foundation and the International AIDS Vaccine Initiative, the report represents the views of many mainstream vaccine researchers.

The report highlights criticisms about the data analysis and conclusions, and the recent decision by the US National Institute for Allergy and Infectious Diseases and the Centers for Disease Control to hold a series of meetings with VaxGen to independently analyse the trial data. It also underscores lessons to be learned from the trial.